Business context and reporting period
Filing identity: Although the request identifies T3 Defense Inc., the supplied Form 10-Q is for Brilliant Acquisition Corporation, a British Virgin Islands blank-check company (SPAC), for the quarter ended September 30, 2023. It reports no operating business or revenue and was still seeking a business combination.
The company had a proposed merger with Nukkleus Inc.; the merger agreement was amended on November 1, 2023. The filing does not report a completed transaction.
Financial results and liquidity
| Metric | Three months ended Sept. 30, 2023 | Nine months ended Sept. 30, 2023 |
|---|---|---|
| Revenue | None | None |
| Operating costs | $116,668 | $459,994 |
| Net loss | $126,062 | $468,928 |
| Basic and diluted loss per share | $0.07 | $0.24 |
| Cash used in operating activities | — | $304,272 |
| Cash used in financing activities | — | $1,198,438 |
At September 30, total assets were $4.608 million, including $4.607 million classified as redeemable shares held in the trust account. Unrestricted operating cash was only $1,520. Current liabilities were $4.651 million, including $2.961 million in related-party promissory notes and $1.221 million due to a related party. The company reported a $1.689 million working-capital deficit excluding trust cash and shareholders’ deficit of $4.669 million. It had no long-term debt disclosed.
Changes versus the prior comparable period
Net loss improved from $578,753 to $126,062 for the quarter and from $1.075 million to $468,928 for the nine-month period. Operating costs also declined: from $480,867 to $116,668 for the quarter and from $1.095 million to $459,994 year to date. These are SPAC administrative and transaction-related costs, not operating-business margins. The prior-year periods included trust interest income; none was reported for 2023. Fair-value changes in warrant liabilities affected reported losses in both years.
Trust-account redemptions reduced redeemable shares from 564,936 at December 31, 2022 to 403,696 at September 30, 2023. The company used $1.729 million for redemption payments during the first nine months of 2023.
Outlook, risks, contingencies, and unusual items
- Management stated that substantial doubt exists about the company’s ability to continue as a going concern, citing minimal unrestricted cash, the working-capital deficit, and the approaching business-combination deadline. The filing says the company must liquidate if it does not complete a transaction or obtain an extension.
- The stated deadline was November 23, 2023, with a possible extension to December 23, 2023 through a further $32,300 trust deposit. A related-party note issued October 20, 2023 funded an extension through November 23. Additional funding was not committed, and sponsor or affiliate loans are discretionary.
- The company had outstanding non-interest-bearing related-party notes and advances. The notes are generally payable upon completion of a business combination; the $1.221 million advance is due on demand.
- Management disclosed a material weakness in internal control over financial reporting concerning accounting for complex warrants and redeemable shares. Remediation efforts were planned, with no assurance they would be effective.
- The filing identifies COVID-19 and the Russia-Ukraine conflict and related sanctions as uncertainties that could affect the search for a target, financing, or a transaction; specific effects were not determinable.
- Warrant liabilities were measured using Level 3 valuation inputs; their fair value was $19,577 at September 30, 2023, up from $10,643 at year-end.
Important facts for investors to verify
- Confirm the issuer: the supplied filing is Brilliant Acquisition Corporation, not T3 Defense Inc.
- Check subsequent filings for the Nukkleus merger’s status, any later deadline extension, and whether the SPAC completed a transaction or liquidated.
- Verify available unrestricted cash and the terms, balances, and repayment status of sponsor- and Nukkleus-related financing.
- Review shareholder redemptions, the remaining trust balance, and any effects on the transaction’s funding and ownership.
- Track remediation of the disclosed material weakness and review any later auditor or management disclosures.